Endocrine Abstracts

Introduction: Metabolic syndrome (MS) is connected to atherogenic dyslipidemia. Data concerning influence of metformin (MET) therapy on lipid profile in nondiabetic women with MS remains unclear.

Aim: To asses the influence of MET on selected lipid, apolipoproteins AI, B concentrations and atherogenic indexes values in young women with MS.

Materials and methods: The study population: 30 women with MS aged 25–45 years before (M₁) and after (M₂) MET therapy (1700 mg per day for 4 months). Control group (C): 15 nonobese women. Total cholesterol (TC), LDL-C, HDL-C, HDL₂-C, triglycerides (TG), apolipoprotein AI (ApoAI) and B (ApoB), fasting glucose and insulin concentrations were estimated. Atherogenic index of plasma (AIP), Castelli index, LDL-C/HDL-C, TC/HDL-C, apoB/apoAI, HOMA, FIRI, QUICKI indexes were estimated. All parameters were evaluated before and after MET.

Results: In M₁ group we found higher TC, LDL-C, TG, ApoB and lower HDL-C, HDL₂-C, ApoAI concentrations than in nonobese women. HDL-C concentration increased and TG decreased significantly after therapy. Atherogenic indexes values were higher in M₁ than in C, significantly decreased after therapy, except for ApoB/AI, and were still higher than in C. Fasting glucose and insulin concentrations, HOMA, FIRI were the highest and QUICKI was the lowest in M₁, did not change after MET.

Coclusions: MET positively modifies lipid profile and atherogenic indexes values in women with MS.